Table 2. Clinical data of included studies (continued).
| Studies | H. pylori eradication group | H. pylori non-eradication group | Definition of metachronous recurrence | Eradication regimen | ||
|---|---|---|---|---|---|---|
| Metachronous recurrence | Total | Metachronous recurrence | Total | |||
| Uemura et al., 1997 (24) | 0 | 65 | 6 | 67 | No* | OMP 20 mg 4 weeks, CM 400 mg 2 weeks → 2nd: OMP 20 mg, AMX 1,500 mg, MZ 500 mg 2 weeks |
| Nakagawa et al., 2006 (25) | 8 | 356 | 129 | 2,469 | No | Mainly LANS 60 mg, CM 400 mg, AMX 1,500 mg 1 week** |
| Fukase et al., 2008 (9) | 9 | 272 (ITT), 255 (PP) | 24 | 272 (ITT), 250 (PP) | No | LANS 60 mg, CM 400 mg, AMX 1,500 mg 1 week. |
| Shiotani et al., 2008 (26) | 9 | 80 | 1 | 11 | No | (OMP 40 mg or LANS 60 mg or RABE 20 mg), CM 400 mg, AMX 1,500 mg 1 week → 2nd PPI, AMX, METRO 750 mg |
| Maehata et al., 2012 (27) | 15 | 177 | 13 | 91 | Yes∥ | (OMP 40 mg or LANS 60 mg or RABE 20 mg), CM 400 mg, AMX 1,500 mg 1 week → 2nd PPI, AMX, METRO 250 mg |
| Seo et al., 2013 (28) | 4 | 41 | 3 | 6 | No | (OMP 40 mg or LANS 60 mg or RABE 40 mg, ESOM 80 mg), CM 1,000 mg, AMX 2,000 mg 1 week |
| Choi et al., 2014 (13) | 10 | 444 (ITT), 439 (PP) | 17 | 457 (ITT), 441 (PP) | Yes† | OMP 40 mg, CM 1,000 mg, AMX 2,000 mg 1 week |
| Bae et al., 2014 (29) | 34 | 485 | 24 | 182 | Yes‡ | (OMP 60 mg or LANS 60 mg or PANTO 80 mg), CM 400 mg, AMX 1,500 mg 1-2 weeks |
| Kwon et al., 2014 (30) | 18 | 214 | 13 | 69 | Yes§ | (OMP 40 mg or LANS 60 mg or RABE 40 mg), CM 400 mg, AMX 1,500 mg 1 week |
| Kim et al., 2014 (31) | 2 | 49 | 16 | 107 | Yes¶ | (OMP 40 mg or RABE 20 mg or PANTO 80 mg), CM 1,000 mg, AMX 2,000 mg 1 week |
*Not defined. However, all the metachronous recurrence were developed after 12 months of endoscopic resection; †New carcinoma occurring at another site in the stomach; ‡New carcinoma occurring after 6 months of endoscopic resection; §New dysplasia or carcinoma (Vienna 3-5) developing in areas other than the site of primary gastric cancers at least 1 yr after the endoscopic resection; ¶Development of new gastric cancer at a previously uninvolved site in the stomach at least 1 yr after endoscopic resection; ∥New carcinoma developing in areas other than the site of primary gastric cancer at least 1 yr after the endoscopic resection; **Multicenter study. The regimen depended on the choice of each institution. The main regimen is described. ITT, intention-to-treat analysis; PP, per-protocol analysis; week; OMP, omeprazole; LANS, lansoprazole; RABE, rabeprazole; ESOM, esomeprazole; PANTO, pantoprazole; CM, clarithromycin; AMX, amoxicillin; METRO, metronidazole.